Want to see AU:EVE full AI Analyst Report?
Top Page
EVE Health Group Limited
(Sydney:EVE)
Select Model
Select Model
Rating:44Neutral
Price Target:
AU$0.02
▼(-25.00% Downside)
Action:Upgraded
Date:09/06/26
The score is primarily held down by weak financial performance (ongoing losses, negative margins, and persistent cash burn), despite a low-debt balance sheet. Technicals add further pressure with the stock below all key moving averages and a negative MACD. Valuation offers limited support due to a negative P/E and no dividend yield data.
Positive Factors
Very low leverage
A debt-light balance sheet reduces refinancing and interest-rate risk while preserving financial flexibility. This gives EVE more capacity to restructure operations and allocate future capital without the additional pressure of substantial debt servicing obligations.
Negative Factors
Persistent cash burn
Consistently negative operating and free cash flow shows that EVE is not funding its activities internally. Continued cash consumption can require external funding or balance-sheet resources, limiting strategic flexibility and increasing the importance of a successful turnaround.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage
A debt-light balance sheet reduces refinancing and interest-rate risk while preserving financial flexibility. This gives EVE more capacity to restructure operations and allocate future capital without the additional pressure of substantial debt servicing obligations.
Read all positive factors
EVE Health Group Limited (EVE) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$5.28M
Dividend YieldN/A
Average Volume (3M)352.87K
Price to Earnings (P/E)―
Beta (1Y)0.40
Revenue Growth-33.53%
EPS Growth42.98%
CountryAU
Employees3
SectorConsumer Defensive
Sector Strength42
IndustryPackaged Foods
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding352,326,600
10 Day Avg. Volume148,205
30 Day Avg. Volume352,871
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.40
Price to Sales (P/S)4.80
P/FCF Ratio-3.18
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
EVE Health Group Limited Business Overview & Revenue Model
Company Description
Based in Subiaco, Australia, Eve Health Group Limited, originally incorporated in 2003 as EVE Investments Limited, is an international provider of health, wellness, and nutritional products. The company operates across Australia, New Zealand, the ...
How the Company Makes Money
EVE primarily makes money by selling its branded health products, generating revenue from product sales through retail, pharmacy, and other distribution channels (including wholesale/distributor arrangements where applicable). Key revenue streams ...
EVE Health Group Limited Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
66
Positive
Cash Flow
21
Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.15M | 1.73M | 2.13M | 2.33M | 2.01M |
| Gross Profit | -106.51K | 824.03K | 876.96K | 827.83K | -1.00M |
| EBITDA | -1.77M | -1.43M | -1.51M | -2.18M | -4.53M |
| Net Income | -1.89M | -1.58M | -1.90M | -4.04M | -5.37M |
Balance Sheet | |||||
| Total Assets | 4.28M | 4.12M | 2.52M | 4.13M | 8.07M |
| Cash, Cash Equivalents and Short-Term Investments | 1.24M | 903.42K | 106.17K | 192.48K | 1.10M |
| Total Debt | 0.00 | 91.28K | 74.85K | 4.28K | 492.39K |
| Total Liabilities | 330.02K | 572.45K | 1.30M | 1.01M | 1.14M |
| Stockholders Equity | 3.95M | 3.55M | 1.22M | 3.12M | 6.93M |
Cash Flow | |||||
| Free Cash Flow | -1.74M | -1.62M | -1.11M | -1.65M | -3.80M |
| Operating Cash Flow | -1.74M | -1.62M | -1.11M | -1.65M | -3.77M |
| Investing Cash Flow | -1.90K | 2.13M | 874.27K | 498.46K | -26.05K |
| Financing Cash Flow | 2.08M | 279.09K | 146.37K | 240.69K | 1.74M |
EVE Health Group Limited Technical Analysis
Negative
0.02
Price Trends
0.02
Negative
0.02
Negative
Market Momentum
>-0.01
Negative
41.17
Neutral
57.78
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:EVE, the sentiment is Negative. The current price of 0.02 is equal to the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 41.17 is Neutral, neither overbought nor oversold. The STOCH value of 57.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:EVE.
EVE Health Group Limited Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
46 Neutral | AU$13.33M | -1.79 | -88.51% | ― | 11.96% | -81.99% | |
44 Neutral | AU$5.28M | -2.34 | -49.07% | ― | -33.53% | 42.98% | |
43 Neutral | AU$13.39M | -4.47 | -12.90% | ― | 0.46% | 46.48% | |
39 Underperform | AU$16.92M | -5.29 | 1795.70% | ― | 0.72% | -486.96% | |
39 Underperform | AU$6.99M | -0.01 | 226.76% | ― | -33.05% | 94.22% |
* Consumer Defensive Sector Average
AU:EVE
EVE Health Group Limited
0.02
-0.02
-50.00%
AU:AHF
Australian Dairy Nutritionals Group
0.02
-0.03
-61.36%
AU:NUC
Nuchev Pty Ltd
0.09
-0.06
-43.33%
AU:HCT
Holista Colltech Limited
0.05
-0.06
-56.19%
AU:NGS
Nutritional Growth Solutions Ltd.
0.02
<0.01
16.67%
EVE Health Group Limited Corporate Events
EVE Health Group to Release 2.25 Million Shares from Escrow
Sep 3, 2026
EVE Health Group Limited has notified investors that 2,250,000 fully paid ordinary shares will be released from escrow on 9 September 2026 in line with ASX Listing Rule 3.10A. The shares were originally issued in May 2026 as consideration under a ...
EVE Health Group files ASX governance key for FY2026
Aug 31, 2026
EVE Health Group Limited has lodged its annual Appendix 4G with the ASX, detailing how it complies with the ASX Corporate Governance Council’s principles and recommendations. The company’s corporate governance statement for the year en...
EVE Health Group Posts Wider Loss as Revenue Slides in 2026
Aug 31, 2026
EVE Health Group reported a sharp deterioration in financial performance for the year ended 30 June 2026, with revenue from ordinary activities falling 33.53% to $1.15 million compared with the prior year. The loss after tax from continuing operat...
EVE Health Advances Libbo Clinical Program and Hits Apixaban Milestone Amid CEO Transition
Aug 7, 2026
EVE Health Group reported progress on its Libbo erectile dysfunction program, finalising the pilot clinical study protocol and engaging a contract research organisation and clinical site to compare its vardenafil oral soluble film with an approved...
EVE Health advances Libbo clinical program and apixaban reformulation as new CEO targets commercial growth
Jul 31, 2026
EVE Health Group has advanced its clinical and technology pipeline in the June quarter, finalising the protocol and engaging a contract research organisation and clinical site for the Libbo pilot study, which will compare its vardenafil oral solub...
EVE Health Director Options Lapse Trims Incentive Exposure
Jul 1, 2026
EVE Health Group has reported a change in the interests of director Stuart Gunzburg, detailing adjustments to his direct and indirect holdings in the company’s securities. The notice records the lapse of 120,000 unlisted options expiring 31 ...
EVE Health Group Options Lapse Adjusts Future Equity Dilution
Jul 1, 2026
EVE Health Group Limited has announced the cessation of 810,000 EVEAI options, which were due to expire on 31 December 2028 with an exercise price of $0.06. The options have lapsed following the failure or impossibility of satisfying the condition...
EVE Health Group trims potential dilution as 4 million options lapse
Jun 19, 2026
EVE Health Group Limited has notified the market of a change to its capital structure, advising that a tranche of options quoted under the ASX code EVEAI has ceased. The affected securities were 4,000,000 options exercisable at $0.06 and expiring ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.